New England Journal of Medicine Publishes Results of Global, Multicenter eNRGy Study Evaluating Zenocutuzumab-zbco (BIZENGRI®) in NRG1+ cancer

BIZENGRI® is the first and only FDA-approved therapy specifically for patients with advanced unresectable or metastatic pancreatic adenocarcinoma or non-small cell lung cancer (NSCLC) who harbor NRG1 gene fusions1 NRG1 gene fusions are best detected by tissue-based RNA next generation...